Company Description
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases.
The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity.
ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Stephen C. Glover |
Contact Details
Address: 217 W. Main Street Somerville, New Jersey 08876 United States | |
| Phone | 908-370-5102 |
| Website | zyversa.com |
Stock Details
| Ticker Symbol | ZVSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001859007 |
| ISIN Number | US98987D2018 |
| Employer ID | 86-2685744 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen C. Glover | Co-Founder, Chairman, Chief Executive Officer and President |
| Peter Wolfe | Chief Financial Officer and Secretary |
| Karen A. Cashmere | Chief Commercial Officer |
| Melda Uzbil O'connell | Senior Vice President of Corporate Development |
| Dr. Pablo A. Guzman FACC, M.D. | Chief Medical Officer, Senior Vice President of Medical Affairs and Chairman of Renal Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2024 | EFFECT | Notice of Effectiveness |
| Jul 12, 2024 | POS AM | Post-Effective amendments for registration statement |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | 10-K/A | [Amend] Annual report |
| Apr 25, 2024 | 8-K | Current Report |
| Apr 17, 2024 | 8-K | Current Report |
| Mar 27, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2024 | 10-K | Annual Report |
| Mar 19, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 8, 2024 | 8-K | Current Report |